Korro Bio Announces Collaboration With Novo Nordisk To Develop Two Therapeutic Candidates, Leveraging Korro's Proprietary OPERA Platform To Enable Its Oligonucleotide-Directed RNA Edits Into Two Undisclosed Targets; Initially For Cardiometabolic...
Korro Bio Announces Collaboration With Novo Nordisk To Develop Two Therapeutic Candidates, Leveraging Korro's Proprietary OPERA Platform To Enable Its Oligonucleotide-Directed RNA Edits Into Two Undisclosed Targets; Initially For Cardiometabolic...
Korro Bio Announces Collaboration With Novo Nordisk To Develop Two Therapeutic Candidates, Leveraging Korro's Proprietary OPERA Platform To Enable Its Oligonucleotide-Directed RNA Edits Into Two Undisclosed Targets; Initially For Cardiometabolic Diseases; Total Deal Value Of Up To $530M In Upfront, Development, And Commercial Milestone Payments, In Addition To Tiered Royalties And R&D Funding
Korro Bio宣佈與諾和諾德展開合作，開發兩個治療候選藥物，利用Korro的獨有OPERA平台將寡核苷酸轉錄RNA編輯技術應用於兩個未公開的靶點，首先針對心血管代謝疾病；總交易價值高達5,3000萬美元，包括預付款、研發及商業里程碑支付以及分階段的版稅和研發資助。
Partnership leverages Korro's proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; initially for cardiometabolic diseases
合作利用Korro獨有的OPERA平台，將寡核苷酸轉錄RNA編輯技術應用於兩個未公開的靶點，首先是針對心血管代謝疾病。
Total deal value of up to $530 million in upfront, development, and commercial milestone payments, in addition to tiered royalties and R&D funding
交易總價值高達5,3000萬美元，包括預付款、研發及商業里程碑支付以及分階段的版稅和研發資助。
CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases, today announced a collaboration with Novo Nordisk, a global healthcare company, to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases. The collaboration brings together Novo Nordisk's deep cardiometabolic disease understanding and drug development experience with Korro's proprietary platform to develop RNA editing product candidates for two undisclosed targets.
馬薩諸塞州劍橋，2024年9月16日（全球新聞線）——Korro Bio, Inc.（Korro）（納斯達克：KRRO），一家專注於基於RNA編輯的潛在新型基因藥物的生物製藥公司，致力於罕見病和高患病率疾病的開發和發現，今天宣佈與全球醫療保健公司諾和諾德展開合作，推動新型基因藥物的發現和開發，首個目標是治療心血管代謝疾病。此次合作將諾和諾德豐富的心血管代謝疾病理解和藥物開發經驗與Korro獨有的平台相結合，開發針對兩個未公開的靶點的RNA編輯產品候選。
譯文內容由第三人軟體翻譯。